TCA
NVCR icon

Trifecta Capital Advisors’s NovoCure NVCR Stock Holding History

Trifecta Capital Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-320
Closed -$5.17K – 451
2023
Q3 		$5.17K Hold
320
– – ﹤0.01% 238
2023
Q2 		$13.3K Hold
320
– – ﹤0.01% 199
2023
Q1 		$19.2K Hold
320
– – 0.01% 186
2022
Q4 		$23.5K Buy
+320
New +$24.1K 0.01% 165

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Trifecta Capital Advisors's NVCR Position: Q4 2023 in Review

Trifecta Capital Advisors sold out of NovoCure (NVCR) in Q4 2023, closing a stake of 320 shares — an estimated $5.17K sold.

Trifecta Capital Advisors first reported a position in NVCR in Q4 2022 and held it in 4 quarters. The position peaked at $23.5K in Q4 2022. 219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.

  • Trifecta Capital Advisors reported no remaining NovoCure position as of Q4 2023 after selling out during the quarter.
  • Trifecta Capital Advisors sold 320 NovoCure shares in Q4 2023, an estimated $5.17K.
  • Trifecta Capital Advisors first reported a position in NovoCure in Q4 2022 and held it in 4 quarters.
  • Trifecta Capital Advisors's NovoCure position peaked at $23.5K in Q4 2022.
  • 219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.

Based on Trifecta Capital Advisors's 13F filing for Q4 2023, filed 25 Jan 2024.